SCHEMBL63875

SCHEMBL63875

O=C(NC12CCC(CC1)Cn1c2nc(C(=O)NCc2ccc(F)cc2)c(O)c1=O)NS(=O)(=O)c1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.45
CYP2C9 P11712 2/20 0.42
CXCR4 P61073 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CCR3 P51677 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ERCC1 P07992 1/20 0.37
FEN1 P39748 1/20 0.37
ERCC4 Q92889 1/20 0.37
KCNE1 P15382 1/20 0.36
CCR1 P32246 1/20 0.36
KCNQ1 P51787 1/20 0.36
EGFR P00533 1/20 0.36
ERBB2 P04626 1/20 0.36
TP53 P04637 1/20 0.35
CALCA P06881 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL63575 0.91 KCNH2 (0.47) KCNH2CYP2C9CXCR4MEN1KMT2A
SCHEMBL52562 0.87 KCNH2 (0.45) KCNH2CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL418372 0.86 KCNH2 (0.47) KCNH2CYP2C9MEN1KMT2ASMN1; SMN2
SCHEMBL64204 0.85 KCNH2 (0.48) KCNH2CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL52470 0.84 KCNH2 (0.49) KCNH2CYP2C9MEN1KMT2ASMN1; SMN2
SCHEMBL52509 0.84 KCNH2 (0.49) KCNH2CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL62729 0.84 KCNH2 (0.42) KCNH2CYP2C9MEN1KMT2ASMN1; SMN2
SCHEMBL62281 0.83 KCNH2 (0.42) KCNH2CYP2C9ALDH1A1MEN1KMT2A
SCHEMBL64481 0.83 KCNH2 (0.45) KCNH2CYP2C9MEN1KMT2ASMN1; SMN2
SCHEMBL64248 0.83 ALDH1A1 (0.47) KCNH2CYP2C9ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG KCNH2 3969/4885CYP2C9 602/4885CXCR4 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.